Sangamo Therapeutics
(SGMO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -85,513 | -50,583 | -30,597 | -97,941 | -74,545 |
| Depreciation Amortization | 5,719 | 3,821 | 1,924 | 9,088 | 6,953 |
| Income taxes - deferred | 0 | N/A | 15 | N/A | 18 |
| Accounts receivable | 3 | 154 | 160 | 397 | -9,171 |
| Other Working Capital | 5 | -2,402 | -77 | 3,951 | -10,830 |
| Other Operating Activity | 6,981 | 4,703 | 2,426 | 17,366 | 23,787 |
| Operating Cash Flow | $-72,805 | $-44,307 | $-26,149 | $-67,139 | $-63,788 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 0 | 0 | 0 | 35,840 | 35,840 |
| PPE Investments | -88 | -24 | N/A | -267 | 360 |
| Other Investing Activity | 0 | 0 | 0 | 1,951 | 0 |
| Investing Cash Flow | $-88 | $-24 | $0 | $37,524 | $36,200 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 58,866 | 39,395 | 10,361 | 29,281 | 22,070 |
| Other Financing Activity | -2,914 | -2,647 | -2,227 | -904 | -684 |
| Financing Cash Flow | $55,952 | $36,748 | $8,134 | $28,377 | $21,386 |
| Exchange Rate Effect | 4,051 | 4,009 | 1,277 | -2,048 | 199 |
| Beginning Cash Position | 43,418 | 43,418 | 43,418 | 46,704 | 46,704 |
| End Cash Position | 30,528 | 39,844 | 26,680 | 43,418 | 40,701 |
| Net Cash Flow | $-12,890 | $-3,574 | $-16,738 | $-3,286 | $-6,003 |
| Free Cash Flow | |||||
| Operating Cash Flow | -72,805 | -44,307 | -26,149 | -67,139 | -63,788 |
| Capital Expenditure | -88 | -24 | N/A | -267 | -115 |
| Free Cash Flow | -72,893 | -44,331 | -26,149 | -67,406 | -63,903 |